| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
ARRY382 manufacturers
- ARRY-382
-
- $70.00
-
2026-08-09
- CAS:1313407-95-2
- Purity: 99.76%
- Supply Ability: 10g
|
| | ARRY382 Basic information |
| Product Name: | ARRY382 | | Synonyms: | ARRY382;Imidazo[1,2-a]pyridine-3-carboxamide, N-[3-cyclopropyl-1-[(6-methyl-2-pyridinyl)methyl]-1H-indazol-4-yl]-7-[2-(4-methyl-1-piperazinyl)ethoxy]-;ARRY 382,ARRY382;RRY-382;N-(3-cyclopropyl-1-((6-methylpyridin-2-yl)methyl)-1H-indazol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)imidazo[1,2-a]pyridine-3-carboxamide;ARRY-382 | | CAS: | 1313407-95-2 | | MF: | C32H36N8O2 | | MW: | 564.68 | | EINECS: | | | Product Categories: | | | Mol File: | 1313407-95-2.mol |  |
| | ARRY382 Chemical Properties |
| density | 1.37±0.1 g/cm3(Predicted) | | solubility | Acetonitrile: Soluble
DMSO: Soluble | | pka | 10.33±0.50(Predicted) | | form | Solid |
| | ARRY382 Usage And Synthesis |
| Uses | ARRY-382 is a potent, oral and highly selective inhibitor of CSF1R/c-Fms with an IC50 of 9 nM. ARRY-382 can be used for the research of advanced or metastatic cancers[1]. | | References | [1] David K Edwards V, et al. Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. Oncotarget. 2018 May 15;9(37):24576-24589. DOI:10.18632/oncotarget.25191 |
| | ARRY382 Preparation Products And Raw materials |
|